[Skip to Content]
[Skip to Content Landing]
May 1963

An Ophthalmoscopic Study of Patients Under Treatment with Thioridazine

Author Affiliations

Costa Mesa, Calif.
Ophthalmologist, Fairview State Hospital.

Arch Ophthalmol. 1963;69(5):578-580. doi:10.1001/archopht.1963.00960040584008

When thioridazine * (2-methylmercapto10-[2-( N-methy1-2-piperidy1 ) ethyl ]-phenothiazine hydrochloride) came to our attention, several members of our staff became impressed with the therapeutic value and minimal side-effects of this phrenotropic agent. Within a short period, over one hundred mentally retarded patients were receiving varying daily dosages of thioridazine for emotional disturbances, behavior and related problems. Since the bibliography on thioridazine is extensive, just a few pertinent references will be given. Kinross-Wright,1 Sandison,2 Jones et al.,3 Hollister and MacDonald,4 Cohen and Pillsbury,5 Oettinger and Simonds,6 Zarling and Hogan,7 Kuberski,8 and Barsa and Saunders9 reported that thioridazine is an effective phenothiazine and, importantly, it produces a lower incidence of side-effects.

Weekley et al.10 reported visual difficulties in 4 out of 29 patients treated with rather large dosages of thioridazine; 2 showed a severe loss of central visual acuity, and all 4 later exhibited

First Page Preview View Large
First page PDF preview
First page PDF preview